HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: jcp.2006.040170v1 60/5/500    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Fons, G. Articles by ten Kate, F. J W Search for Related Content PubMed PubMed Citation Articles by Fons, G. Articles by ten Kate, F. J W

Validation of tissue microarray technology in endometrioid cancer of the endometrium

¹ Academic Medical Centre, Department of Obstetrics and Gynaecology, Amsterdam, The Netherlands
² Dr Pirngadi Hospital, Department of Anatomical Pathology, Medan, Indonesia
³ Academic Medical Centre, Department of Pathology, Amsterdam, The Netherlands

Correspondence to:
Dr G Fons
Academic Medical Centre Department of Obstetrics and Gynaecology Meibergdreef 9 1100 DD Amsterdam The Netherlands;g.fons{at}amc.uva.nl Aim: To validate tissue microarray (TMA) for endometrial cancer by comparing immunohistochemical staining results of triplicate core biopsies on TMA with the results of full-section analysis.

Methods: The study material consisted of slides and selected tissue blocks of 41 patients with endometrioid cancer of the endometrium. A TMA was constructed. Both the TMA and the slides were stained with the same antibodies against progesterone receptor (PR), oestrogen receptor, p53 and epithelial membrane antigen (EMA). Concordance between results was expressed as the statistic.

Results: Concordance between the staining results of TMA and whole slides was good for PR ( = 0.69), oestrogen receptor ( = 0.78), p53 ( = 0.81) and EMA ( = 0.72). Concordance between the results on TMA and slides depends on the number of assessable cores per tumour. Three assessable cores per case result in outcomes that are at least 94% similar to those achieved using conventional tissue sections with a two-class scoring system. This is independent of focal or diffuse staining patterns.

Conclusion: TMA is a useful tool for further analysis of the molecular pathways in endometrial cancer. The effect of selection has to be taken into account when the prognostic value of protein expression on TMA is determined.